呼吸 Vol.30 No.3 増刊号 2011年3月

出版社： 呼吸研究(旧：レスピレーションリサーチファンデーション）
著者：
発行日： 2011-03-24
分野： 臨床医学：内科  >  呼吸器一般
ISSN： 02869314
電子書籍版： 2011-03-24
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,310 円(税込)

購入する

目次

  • 表紙
  • 目次
  • 『呼吸』エッセンシャルズ - COPD - 発行に寄せて
  • ガイドライン
  • COPDガイドライン2009
  • 病態
  • COPDと気管支喘息
  • COPDと遺伝子多型
  • COPDと細胞の老化
  • 呼吸困難感の定量的評価
  • ICの測定と臨床的有用性
  • 喘鳴を伴う呼吸困難
  • 日本人を対象としたCOPD質問票の有用性についての検討
  • 日本人COPD患者へのCOPDアセスメントテストの使用 - COPD特異的St. George' s Respiratory Questionnaire ( SGRQ - C ) との相関性 -
  • 診断
  • スパイロメトリー
  • フローボリューム
  • インパルスオシレーション法による肺メカニクス解析
  • 体プレチスモグラフィ
  • 肺拡散能力検査
  • エッセンシャル6回シリーズ 「原理の理解から実践と解釈まで」 ( 4 ) 血液ガス
  • 運動負荷試験による呼吸機能の評価
  • 歩行負荷テスト - 6MWTとSWT -
  • 薬物療法
  • ドーズカウンター付メプチンMDI製剤
  • プロカテロールのCOPDへのアシストユース - 呼吸機能の改善と患者活動性の向上 -
  • 長時間作用性β2刺激薬 - サルメテロール -
  • ツロブテロール貼付薬 ( ホクナリンテープ ( R ) ) の有用性
  • 長時間作動型吸入抗コリン薬 : チオトロピウム
  • チオトロピウム : ハンディヘラーからレスピマットへ
  • アドエア ( R ) ( サルメテロール / プロピオン酸フルチカゾン合剤 ) - その作用機序と臨床成績 -
  • 低用量テオフィリンの抗炎症作用機序 : エピジェネティック作用薬
  • バレニクリン
  • 非薬物療法
  • 呼吸リハビリテーションの科学的エビデンス
  • COPDの病態と栄養をめぐる新知見
  • 病診連携 ( 在宅療法 )
  • 在宅リハビリテーション - 地域連携 ( リハビリテーション ) を含む - ( 1 )
  • 在宅呼吸リハビリテーション - 地域連携の構築 - ( 2 )
  • 在宅呼吸療法
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

ガイドライン

P.6 掲載の参考文献
1) Canadian Thoracic Society Workshop Group. Guidelines for the assessment and management of chronic obstructive pulmonary disease. CMAJ 147 : 420-428, 1992.
PubMed
2) 日本呼吸器学会COPDガイドライン作成委員会. COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン, メディカルレビュー社. 東京 : 1999
 
3) 日本呼吸器学会COPDガイドライン第3版作成委員会. COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン 第3版. メディカルレビュー社. 東京 : 2009
 

病態

P.17 掲載の参考文献
1) Tattersfield AE, Knox AJ, Britton JR, Hall IP. Asthma. Lancet 360 : 1313-1322, 2002
PubMed
2) Busse WW, Lemanske RF. Asthma. N Engl J Med 344 : 350-362, 2001
PubMed
3) Matsunaga K, Yanagisawa S, Ichikawa T, Ueshima K, Akamatsu K, Hirano T, Nakanishi M, Yamagata T, Minakata Y, Ichinose M. Airway cytokine expression measured by means of protein array in exhaled breath condensate : Correlation with physiologic properties in asthmatic patients. J Allergy Clin Immunol 118 : 84-90, 2006
PubMed
4) Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 56 : 515-548, 2004
PubMed
5) Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, Ligabue G, Ciaccia A, Saetta M, Papi A. Differences in Airway Inflammation in Patients with Fixed Airflow Obstruction Due to Asthma or Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 167 : 418-424, 2003
PubMed
6) Tomaki M, Ichinose M, Miura M, Hirayama Y, Yamauchi H, Nakajima N, Shirato K. Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis. Am J Respir Crit Care Med 151 : 613-617, 1995
PubMed
7) Ichinose M, Sugiura H, Yamagata S, Koarai A, Shirato K. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. Am J Respir Crit Care Med 162 : 701-706, 2000
PubMed
8) Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122 : 47-55, 2002
PubMed
9) Barnes PJ. Small airways in COPD. N Engl J Med 350 : 2635-2637, 2004
PubMed
10) Hamid Q, Song Y, Kotsimbos TC, Bai TR, Hegele RG, Hogg JC. Inflammation of small airways in asthma. J Allergy Clin Immunol 100 : 44-51, 1997
PubMed
11) Cockcroft DW. In : Barnes PJ, Grunstein MM, Leff AR, Woolcock AJ, eds. Airway responsiveness In Asthma, Lippincott-Raven Publishers. Philadelphia : pp.1253-1266, 1997
 
12) Ichinose M, Takahashi T, Sugiura H, et al. Baseline airway hyperresponsiveness and its reversible component : role of airway inflammation and caliber. Eur Respir J 15 : 248-253, 2000
PubMed
13) Ichinose M, et al. Protection against bradykinin-induced bronchoconstriction in asthmatic patients by neurokinin receptor antagonist. Lancet 340 : 1248-1251, 1992
PubMed
14) Ichinose M, et al. A neurokinin 1-receptor antagonist improves exercise-induced airway narrowing in asthmatic patients. Am J Respir Crit Care Med 153 : 936-941, 1996
PubMed
15) Barnes PJ, Pederson S, Busse WW. Efficacy and Safety of Inhaled Corticosteroids : New Developments. Am J Respir Crit Care Med 157 : S1-S53, 1998
 
16) 日本呼吸器学会COPDガイドライン第2版作成委員会. COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン第2版, メディカルレビュー. 東京 : 2004
 
17) Fukuchi Y, Nishimura M, Ichinose M, Adachi M, Nagai A, Kuriyama T, Takahashi K, Nishimura K, Ishioka S, Aizawa H, Iqbal A. Chronic obstructive pulmonary disease (COPD) in Japan : The Nippon COPD Epidemiology (NICE) Study. Respirology 9 : 458-465, 2004
 
P.24 掲載の参考文献
1) Kueppers F, Miller RD, Gordon H, Hepper NG, Offord K. Familial prevalence of chronic obstructive pulmonary disease in a matched pair study. Am J Med 63(3) : 336-342, 1977
 
2) Joost O, Wilk JB, Cupples LA, Harmon M, Shearman AM. Baldwin CT. O'Connor GT, Myers RH, Gottlieb DJ. Genetic loci influencing lung function : a genome-wide scan in the Framingham Study. Am J Respir Crit Care Med 165(6) : 795-799, 2002
PubMed
3) Wilk JB. DeStefano AL, Joost O, Myers RH, Cupples LA, Slater K. Atwood LD, Heard-Costa NL, Herbert A, O'Connor GT, Gottlieb DJ. Linkage and association with pulmonary function measures on chromosome 6q27 in the Framingham Heart Study. Hum Mol Genet 12(21) : 2745-2751. 2003
PubMed
4) Wilk JB, DeStefano AL. Arnett DK, Rich SS, Djousse L, Crapo RO, Leppert MF, Province MA, Cupples LA, Gottlieb DJ, Myers RH. A genome-wide scan of pulmonary function measures in the National Heart, Lung and Blood Institute Family Heart Study. Am J Respir Crit Care Med 167(11) : 1528-1533, 2003
PubMed
5) Silverman EK, Chapman HA, Drazen JM, Weiss ST, Rosner B, Campbell EJ. O'Donnell WJ. Reilly JJ. Ginns L. Mentzer S. Wain J. Speizer FE. Genetic epidemiology of severe. early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 157 (6 Pt 1) : 1770-1778, 1998
 
6) Silverman EK. Mosley JD. Palmer LJ, Barth M, Senter JM, Brown A, Drazen JM, Kwiatkowski DJ, Chapman HA, Campbell EJ, Province MA, Rao DC, Reilly JJ, Ginns LC, Speizer FE, Weiss ST. Genome-wide linkage analysis of severe, early-onset chronic obstructive pulmonary disease : airflow obstruction and chronic bronchitis phenotypes. Hum Mol Genet 11(6) : 623-632, 2002
PubMed
7) Palmer LJ, Celedon JC, Chapman HA, Speizer FE, Weiss ST, Silverman EK. Genome-wide linkage analysis of bronchodilator responsiveness and post-bronchodilator spirometric phenotypes in chronic obstructive pulmonary disease. Hum Mol Genet 12(10) : 1199-1210, 2003
PubMed
8) Sandford AJ, Chagani T, Weir TD, Connett JE, Anthonisen NR, Pare PD. Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med 163(2) : 469-473, 2001
PubMed
9) Joos L, McIntyre L, Ruan J, Connett JE, Anthonisen NR, Weir TD, Pare PD, Sandford AJ. Association of IL-1 beta and IL-1 receptor antagonist haplotypes with rate of decline in lung function in smokers. Thorax 56(11) : 863-866, 2001
 
10) Joos L, He JQ, Shepherdson MB, Connett JE, Anthonisen NR, Pare PD, Sandford AJ. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 11(5) : 569-576, 2002
PubMed
11) Joos L, Weir TD, Connett JE, Anthonisen NR, Woods R, Pare PD, Sandford AJ. Polymorphisms in the beta2 adrenergic receptor and bronchodilator response, bronchial hyperresponsiveness and rate of decline in lung function in smokers. Thorax 58(8) : 703-707, 2003
PubMed
12) He JQ, Connett JE, Anthonisen NR, Sandford AJ. Polymorphisms in the IL13, IL13RA1 and IL4RA genes and rate of decline in lung function in smokers. Am J Respir Cell Mol Biol 28(3) : 379-385, 2003
PubMed
13) He JQ, Connett JE, Anthonisen NR, Pare PD, Sandford AJ. Glutathione S-transferase variants and their interaction with smoking on lung function. Am J Respir Crit Care Med 170(4) : 388-394, 2004
PubMed
14) He JQ, Burkett K, Connett JE, Anthonisen NR, Pare PD, Sandford AJ. Interferon gamma polymorphisms and their interaction with smoking are associated with lung function. Hum Genet 119(4) : 365-375, 2006
PubMed
15) Hersh CP, Demeo DL, Lange C, Litonjua AA. Reilly JJ, Kwiatkowski D, Laird N, Sylvia JS, Sparrow D, Speizer FE, Weiss ST, Silverman EK. Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol 33(1) : 71-78, 2005
PubMed
16) Wilk JB, Herbert A, Shoemaker CM, Gottlieb DJ, Karamohamed S. Secreted modular calcium-binding protein 2 haplotypes are associated with pulmonary function. Am J Respir Crit Care Med 175(6) : 554-560, 2007
PubMed
17) Celedon JC, Lange C, Raby BA, Litonjua AA, Palmer LJ, DeMeo DL, Reilly JJ, Kwiatkowski DJ, Chapman HA, Laird N, Sylvia JS, Hernandez M, Speizer FE, Weiss ST, Silverman EK. The transforming growth factor-beta1(TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet 13(15) : 1649-1656, 2004
PubMed
18) Demeo DL, Mariani TJ. Lange C, Srisuma S, Litonjua AA, Celedon JC, Lake SL, Reilly JJ, Chapman HA, Mecham BH, Haley KJ, Sylvia JS, Sparrow D, Spira AE, Beane J, Pinto-Plata V, Speizer FE, Shapiro SD, Weiss ST, Silverman EK. The SERPINE2 Gene Is Associated with Chronic Obstructive Pulmonary Disease. Am J Hum Genet 78(2) : 253-264, 2006
PubMed
19) Chappell S, Daly L, Morgan K, Baranes TG, Roca J, Rabinovich R, Millar A, Donnelly SC, Keatings V, MacNee W, Stolk J, Hiemstra PS, Miniati M, Monti S, O'Connor CM, Kalsheker N. The SERPINE2 gene and chronic obstructive pulmonary disease. Am J Hum Genet 79(1) : 184-186 ; author reply 186-187, 2006
 
20) Zhu G, Warren L, Aponte J, Gulsvik A, Bakke P, Anderson WH, Lomas DA, Silverman EK, Pillai SG. The SERPINE2 gene is associated with chronic obstructive pulmonary disease in two large populations. Am J Respir Crit Care Med 176(2) : 167-173, 2007
PubMed
21) Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2006. Available from (http://www.goldcopd.org.)
 
22) Huang SL, Su CH, Chang SC. Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med 156(5) : 1436-1439, 1997
PubMed
23) Sakao S, Tatsumi K, Igari H, Shino Y, Shirasawa H, Kuriyama T. Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163(2) : 420-422, 2001
PubMed
24) Tanaka G, Sandford AJ, Burkett K, Connett JE, Anthonisen NR, Pare PD, He JQ. Tumour necrosis factor and lymphotoxin A polymorphisms and lung function in smokers. Eur, Respir J 29(1) : 34-41, 2007
PubMed
25) Bayley JP, Ottenhoff TH, Verweij CL. Is there a future for TNF promoter polymorphisms? Genes Immun 5(5) : 315-329, 2004
 
26) Knight JC, Keating BJ, Kwiatkowski DP. Allele-specific repression of lymphotoxin-alpha by activated B cell factor-1. Nat Genet 36(4) : 394-399, 2004
PubMed
P.30 掲載の参考文献
1) Jeyapalan JC, Sedivy JM. Cellular senescence and organismal aging. Mech Aging Dev 129 : 7-8. 2008
 
2) Herbig U, Ferreira M, Condel L, Carey JD, Sedivy JM. Cellulae senescence in aging primates. Science 311 : 1257, 2006
 
3) Schimitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW. Senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109 : 335-346, 2002
 
4) Minamoto T, Komuro L. Role of telomeres in vascular senescence. Front Biosci 13 : 2971-2979, 2008
 
5) Price JS, Waters JC, Darrah C, Penninngton C, Edwards DR, Donell ST, Clark LM. The role of chondrocyte senescence in osteoarthritis. Aging Cell 1 : 57-65, 2002
 
6) Campisi J. Senescent cells. tumor suppression, and organismal aging : good citizens, bad neghbors. Cell 120 : 513-532, 2005
PubMed
7) Chung HY, Kim HJ, Kim KW, Choi JS, Yu BP. Molecular inflammation hypothesis of aging based on the anti-aging mechanism of calorie restriction. Microsc Res Tech 59 : 264-272. 2002
PubMed
8) Yokohori N, Aoshiba K, Nagai A. Increased levels of cell death and proliferation in alveolar wall cells in patients with pulmonary emphysema. Chest 125 : 626-632, 2004
PubMed
9) Calabrese F, Giacometti C, Beghe B, Rea F, Loy M, Zuin R, Marulli G, Baraldo S, Saetta M, Valente M. Marked alveolar apoptosis/proliferation imbalance in end-stage emphysema. Respir Res 10 : 14, 2006
 
10) Tsuji T, Aoshiba K, Nagai A. Cigarette smoke induces senescence in alveolar epithelial cells. Am J Respir Cell Mol Biol 31 : 653-649, 2004
 
11) Nyunoya T, Monick MM, Klingelhutz A, Yarovinsky TO. Cagley JR, Hunninghake GW. Cigarette smoke induces cellular senescence. Am J Respir Cell Moll Biol 35 : 681-688, 2006
 
12) Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence in pulmonary emphysema patients. Am J Respir Crit Care Med 174 : 886-893, 2006
PubMed
13) Muller KC, Welker CL, Paasch K, Feindt B, Erpenbeck VJ, Hohlfeld JM, Krug N, Nakashima M, Branscheid D, Magnussen H, Jorres RA, Holtz O. Lung fibroblasts from patients with emphysema show markers of senescence in vitro. Respir Res 7 : 32, 2006
 
15) Suzuki T, Minagawa S, Michishita E, Ogino H, Fujii M, Mitsui Y, Ayusawa D. Induction of senescence-associated genes by 5-bromodeoxyuridine in HeLa cells. Exp Gerontol 36 : 465-474, 2001
PubMed
16) Chung HY, Kim HJ, Kim KW, Choi JS, Yu BP. Molecular inflammation hypothesis of aging based on the anti-aging mechanism of calorie restriction. Microsc Res Tech 59 : 264-272, 2002
PubMed
17) Boren E, Gershwin ME. Inflamm-aging : autoimmunity, and the immune-risk phenotype. Autoimmunity Rev 3 : 401-406, 2004
PubMed
18) Bruunsgaard H, Pedersen BK. Age-related inflammatory cytokines and disease. Immunol Allergy Clin North Am 23 : 15-39, 2003
PubMed
19) Aoshiba K, Nagai A. Chronic lung inflammation in aging mice. FEBS Lett 581 : 3512-3516, 2007
PubMed
20) Meyer KC, Rosenthal NS, Soergel P, Peterson K, Neutrophils and low-grade inflammation in the seemingly normal aging human lung. Mech, Ageing Dev 104 : 169-181, 1996
 
14）Zhang H, He B, Wang x. The changes of Clara cell in the distal conducting airways of patients with COPD. Zhonghua Jie He He Hu Xi Za Zhi 24 : 524-526, 2001
PubMed
P.36 掲載の参考文献
1) Guz A. Chapter 16. Respiratory sensation. In : Adams L, Guz A, eds. Respiratory sensation. Lung Biology in Health and Disease, Volume 90, Mercel Dekker, Inc. New York, USA : pp.389-395, 1996
 
2) 岡部慎一 菊池喜博. 呼吸困難評価法. 呼吸 12(3) : 324-327, 1993
 
3) Fletcher CM. The clinical diagnosis of pulmonary emphysema. Proc R Soc Med 45 : 577-584, 1952
PubMed
4) Mahler D, Wells C. Evaluation of clinical methods for rating dyspnea. Chest 93 : 580-586, 1988
PubMed
5) Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserber agreement, and physiologic correlates of two new clinical index. Chest 85 : 751-758, 1984
PubMed
6) Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 145 : 1321-1327, 1992
 
7) Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350(10) : 1005-1012, 2004
PubMed
8) 瀧島任ほか. 10分間歩行距離法による運動能力の評価. 厚生省特定疾患「呼吸不全」調査研究班. 昭和61年報告書 : pp 104-106, 1984
 
9) ATS Statement. Guidelines for the Six-Minute Walk Test. Am J Respir Crit Care Med 166 : 111-117, 2002
PubMed
10) Enright PL. The six-minute walk test. Respir Care 48 : 783-785, 2003
PubMed
11) van Stel HF, Bogaard JM, Rijssenbeek-Nouwens LH, Colland VT. Multivariable assessment of the 6-min walking test in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163 : 1567-1571, 2001
PubMed
12) Teramoto S, Ohga E, Ishii T, Yamaguchi Y, Yamamoto H, Matsuse T. Reference value of six-minute walking distance in healthy middle-aged and older subjects. Eur Respir J 15 : 1132-1133, 2000
 
13) Teramoto S, Matsuse T, Ouchi Y. Is the symptomatic improvement after lung volume reduction surgery correlated with FEV1 in patients with diffuse emphysema? Chest 111 : 1144-1145, 1997
PubMed
14) Stevens SS. Neural events and the psychophysical law. Science 170 : 1043-1050, 1970
PubMed
15) Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14 : 377-381, 1982
PubMed
16) Aitken RC. Measurement of feelings using visual analogue scales. Proc R Soc Med 62 : 989-993, 1969
PubMed
17) Teramoto S, Fukuchi Y, Nagase T, Matsuse T, Shindo G, Orimo H. Quantitative assessment of dyspnea during exercise before and after bullectomy for giant bulla. Chest 102 : 1362-1366, 1992
PubMed
18) Teramoto S, Fukuchi Y, Orimo H. Effects of inhaled anticholinergic drug on dyspnea and gas exchange during exercise in patients with chronic obstructive pulmonary disease. Chest 103 : 1774-1782, 1993
PubMed
19) Kikuchi Y, Okabe S, Tamura G, Hida W, Homma M, Shirato K, Takishima T. Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma. N Engl J Med 330(19) : 1329-1334, 1994
 
20) O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158 : 1557-1565, 1998
PubMed
21) O'Donnell DE. Assessment of bronchodilator efficacy in symptomatic COPD : is spirometry useful? Chest 117(2 Suppl) : 42S-47S, 2000
 
P.44 掲載の参考文献
1) Federation of American Societies for Experimental Biology. Standardization of definitions and symbols in respiratory physiology. Fed Proc 9 : 602, 1950
 
2) 日本呼吸器学会. 呼吸器学用語集 (http://www.jrs.or.jp/publication/index.html) (Last update 2005.9.21). 日本呼吸器学会. 東京 : 2005
 
3) Murariu C, Ghezzo H, Milic-Emili J, Gautier H. Exercise limitation in obstructive lung disease. Chest 114 : 965-968, 1998
PubMed
4) Milic-Emili J. Inspiratory capacity and exercise tolerance in chronic obstructive pulmonary disease. Can, Respir J 7 : 282-285, 2000
PubMed
5) O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158 : 1557-1565, 1998
PubMed
6) O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anti-cholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160 : 542-549, 1999
PubMed
7) Diaz O, Villafranca C, Ghezzo H, Borzone G, Leiva A, Milic-Emili J, Lisboa C. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J 16 : 269-275, 2000
 
8) Diaz O, Villafranca C, Ghezzo H, Borzone G, Leiva A, Milic-Emili J, Lisboa C. Breathing pattern and gas exchange at peak exercise in COPD patients with and without tidal flow limitation at rest. Eur Respir J 17 : 1120-1127, 2001
PubMed
9) O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 : 770-777, 2001
PubMed
10) 黒澤一. 呼吸機能検査(スパイログラム) : 一ノ瀬正和, 編, COPD診療マニュアル-病態理解から薬物療法・管理まで-, 南江堂. 東京 : pp.17-28, 2005
 
11) Di Marco F, Milic-Emili J, Boveri B, Carlucci P, Santus P, Casanova F, Cazzola M, Centanni S. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 21 : 86-94, 2003
PubMed
12) 黒澤一 菊池喜博. COPD. 呼吸 16(12) : 1432-1436, 1997
 
13) 黒澤一. 日常診療に活かす肺機能検査 呼吸と循環 52 : 597-606, 2004
 
14) O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation : the role of lung hyperinflation. Am Rev Respir Dis 148 : 1351-1357, 1993
PubMed
15) Stubbing DG, Pengelly LD, Morse JLC, Jones NL. Pulmonary mechanics during exercise in subjects with chronic airflow limitation. J Appl Physiol 49 : 511-515, 1980
 
16) Yan S, Kaminski D, Sliwinski P. Reliability of inspiratory capacity for estimating end-expiratory lung volume changes during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 156 : 55-59, 1997
PubMed
17) O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23 : 832-840, 2004
PubMed
18) O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 24:86-94, 2004
PubMed
19) Belman MJ, Botnick WC, Shin JW. Inhaled bron-chodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153:967-975, 1996
 
20) Boni E, Corda L, Franchini D, et al. Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest. Thorax 57:528-532, 2002
PubMed
21) Calverley PMA, Koulouris NG. Flow limitation and dynamic hyperinflation : key concepts in modern respiratory physiology. Eur Respir J 25:186-199, 2005
PubMed
22) Tantucci C, Duguet A, Similowski T, Zelter M, Derenne JP, Milic-Emili J. Effect of salbutamol on dynamic hyper-inflation in chronic obstructive pulmonary disease. Eur Respir J 12:799-804, 1998
 
23) Burrows B, Earle RH. Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients. N Engl J Med 280:397-404, 1969
PubMed
24) Gerardi DA, Lovett L, Bennoti-Connors ML, Reardon JZ, Zu Wallack R. Variables related to increased mortality following out-patient pulmonary rehabilitation. Eur Respir J 9:431-435, 1996
 
25) Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance : change over time and value as a predictor of survival in severe COPD. Eur Respir J 23:431-435, 2004
 
26) Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factor related to mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167:544-549, 2003
PubMed
27) Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 121:1434-1440, 2002
PubMed
28) Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass, index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350:1005-1012, 2004
PubMed
29) Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR. Inspiratory-to-Total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171:591-597, 2005
PubMed
30) Kurosawa H, Kohzuki M. Images in Clinical Medicine : Dynamic Airway Narrowing. N Engl J Med 350:1036, 2004
PubMed
31) 黒澤一 飛田渉. COPDの呼吸機能. 呼吸と循環 52:1215-1222, 2004
 
32) Koulouris NG, Dimopoulou I, Valta P, Finkelstein R, Cosio MG, Milic-Emili J. Detection of expiratory flow limitation during exercise in COPD patients. J Appl Phsysiol 82 : 723-731, 1997
PubMed
33) Kosmas EN, Milic-Emili J, Polychronaki A, Dimitroulis I, Retsou S, Gaga M, Koutsoukou A, Roussos Ch, Koulouris NG. Exercise-induced flow limitation, dynamic hyperinflation and exercise capacity in patients with bronchial asthma. Eur Respir J 24:378-384, 2004
PubMed
34) Gelb AF, Gutierrez CA, Weisman IM, Newsom R, Taylar CF, Zamel N. Simplified detection of dynamic hyperinflation. Chest 126:1855-1860, 2004
 
35) Vogiatzis I, Georgiadou O, Golemati S, Aliverti A, Kosmas E, Kastanakis E, Geladas N, Koutsoukou A, Nanas S, Zakynthinos S, Roussos C. Patterns of dynamic hyperinflation during exercise and recovery in patients with severe chronic obstructive pulmonary disease. Thorax 60:723-729, 2005
PubMed
36) Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163:1395-1399, 2001
PubMed
37) Gigliotti F, Coli C, Bianchi R, Grazzini M, Stendardi L, Castellani C, Scano G. Arm exercise and hyperinflation in patients with COPD : effect of arm training. Chest 128:1225-1232, 2005
PubMed
38) Puente-Maestu L, Garcia de Pedro J, Martinez-Abad Y. Ruiz de Ona JM, Llorente D, Cubillo JM. Dyspnea, ventilatory pattern, and changes in dynamic hyperinflation related to the intensity of constant work rate exercise in COPD. Chest 128:651-656, 2005
 
39) Porszasz J, Emtner M, Goto S, Somfay A, Whipp BJ, Casaburi R. Exercise training decreases ventilatory requirements and exercise-induced hyperinflation at submaximal intensities in patients with COPD. Chest 128:2025-2034, 2005
PubMed
40) Martinez FJ, de Oca MM, Whyte RI, Stetz J, Gay SE, Celli BR. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 155:1984-1990, 1997
PubMed
P.51 掲載の参考文献
1) National Institute of Health, National Heart, Lung and Blood Institute, Global Strategy for Asthma Management and Prevention : pp.64-73, 2006
 
2) 厚生労働省免疫・アレルギー研究班. 喘息予防・管理ガイドライン2006, 協和企画. 東京 : pp.109-121, 2006
 
3) Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106(2):196-204, 1987
PubMed
4) Postma DS. When can an exacerbation of COPD be treated at home? Lancet 351:1827-1828, 1998
PubMed
5) National Institute of Health, National Heart, Lung and Blood Institute, Global Initiative for Chronic Obstructive Lung Disease. 2006 : pp.74-81, 2006
 
6) 日本呼吸器学会 NPPV ガイドライン作成委員会, 編, NPPV ガイドライン, 日本呼吸器学会. 東京 : pp.34-37, 2006
 
7) 日本呼吸器学会 COPD ガイドライン第2版作成委員会, 編, COPD診断と治療のためのガイドライン第2版, 日本呼吸器学会. 東京 : pp.112-126, 2004
 
8) Maisel AM, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161-167, 2002
 
9) Wang CS. FitzGerald JM, Schulzer M, et al. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA 294(15):1944-1956, 2005
PubMed
10) 循環器病の診断と治療に関するガイドライン合同研究班, 編, 急性重症心不全治療ガイドライン. Jpn Circ J 64(Suppl IV):1129-1165, 2000
 
P.55 掲載の参考文献
1) Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, updated 2004, Accessed November 8, 2005 (www.goldcopd.com.)
 
2) Price DB, Tinkelman DG, Halbert RJ, Nordyke RJ, Isonaka S, Nonikov D, Juniper EF, Freeman D, Hausen T, Levy ML, Østrem A, ven der Molen T, van Schayck CP. Symtom-based questionnaire for identifying COPD in smokers. Respiration 73:285-295, 2006
 
3) Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ, Isonaka S, Nonikov D, Juniper EF, Freeman D, Hausen T, Levy ML, Østrem A, ven der Molen T, van Schayck CP. Symptom-based questionnaire for differentiating COPD and asthma. Respiration 73:296-305, 2006
 
4) Price DB, Tinkelman DG, Nordyke RJ, Isonaka S, Halbert RJ. Scoring system and clinical application of COPD diagnostic questionnaires. Chest 129:1531-1539, 2006
PubMed
P.58 掲載の参考文献
1) 政府統計(e-stat) : 平成20年人口動態統計(available from http://www.e-stat.go.jp/. accessed 2010-05-14)
 
2) 一ノ瀬正和 相澤久道 石坂彰敏 永井厚志 福地義之助 Hana Muellerova Martin Crane. 日本における慢性閉塞性肺疾患(COPD)患者の大規模電話実態調査-Confronting COPD Japan Survey-. 日呼吸会誌 45(12):927-935. 2007
Medical*Online
3) 永井厚志ほか. 第I章 定義・疫学・危険因子・病理・病因 F. 病態生理 : 日本呼吸器学会COPDガイドライン第3版作成委員会, COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン 第3版 (株)メディカルレビュー社. 東京 : pp.23-29, 2009
 
4) Jones PW. Quirk FH. Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation : the St. George's Respiratory Questionnaire. Am Rev Respir Dis 145:1321-1327, 1992
 
5) Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 42:773-778, 1987
PubMed
6) Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Leidy NK. Development and first validation of the COPD Assessment Test. Eur Respir J 34:648-654, 2009
 
7) 相澤久道 津田徹 末松利加 蒲原くみ惠 荒川一郎. COPD Assessment Test(CAT) 日本語版の言語的妥当性の検討. 日呼吸会誌 48(増刊号):321, 2010
 
8) COPD アセスメントテスト(available from http://www.catestonline.org/english/index_Japan.htm. accessed 2010-05-14).
 
9) Meguro M, Barley EA, Spencer S, Jones PW. Development and validation of an improved. COPD-specific version of the St. George Respiratory Questionnaire. Chest 132:3456-3463, 2007
 

診断

P.77 掲載の参考文献
1) American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 152:1107-1136, 1995
PubMed
2) Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. Eur Respir J 26:319-338, 2005
PubMed
3) 日本呼吸器学会肺生理専門委員会, 編, 呼吸機能検査ガイドライン : 2004
 
4) Hyatt RE, Schilder DP, Fry DL. Relationship Between Maximum Expiratory Flow and Degree of Lung Inflation. J Appl Physiol 13:331-336, 1958
PubMed
5) Hyatt RE. Expiratory flow limitation. J Appl Physiol 55(1 Pt 1):1-7, 1983
 
6) Jere M, Turner JM, Macklem PT, Little JB. Significance of the relationship between lung recoil and maximum expiratory flow. J Appl Physiol 22(1):95-108, 1967
 
7) Pride NB, Permutt S, Riley RL, Bromberger-Barnea B. Determinants of maximal expiratory fEbw from the lungs. J Appl Physiol 23(5):646-662, 1967
 
8) Stanley VD, Elliott EA. Wave-speed limitation on expiratory flow-a unifying concept. J Appl Physiol 43(3):498-515, 1977
 
9) D'Angelo E, Prandi E, Milic-Emili J. Dependence of maximal flow-volume curves on time course of preceding inspiration. J Appl Physiol 75(3):1155-1159, 1993
PubMed
10) D'Angelo E, Prandi E, Marazzini L, Milic-Emili J. Dependence of maximal flow-volume curves on time course of preceding inspiration in patients with chronic obstruction pulmonary disease. Am J Respir Crit Care Med 150:1581-1586, 1994
PubMed
11) Omar T, Alawadhi H, Soubani AO, Tzelepis GE. Peak Expiratory Flow With or Without a Brief Postinspiratory Pause. Chest 128:442-445, 2005
PubMed
12) Malmberg P, Larsson K, Sundblad BM, Zhiping W. Importance of the time interval between FEV 1 measurements in a methacholine provocation test. Eur Respir J 6:680-686, 1993
 
P.84 掲載の参考文献
1) Ludwig MS, Robatto FM, Simard S, Stamenovic D, Fredberg JJ. Lung tissue resistance during contractile stimulation : structural damping decomposition. J Appl Physiol 72:1332-1337, 1992
PubMed
2) Mead J. Contribution of compliance of airways to frequency-dependent behavior of lungs. J Appl Physiol 26:670-673, 1969
PubMed
3) DuBois AB, Brody AW, Lewis DH, Burgess BF Jr. Oscillation mechanics of lungs and chest in man. J Appl Physiol 8:587-594, 1956
 
4) Takishima T. Hida W. Sasaki H, Suzuki S, Sasaki T. Direct-writing recorder of the dose-response curves of the airway to methacholine. Clinical application. Chest 80:600-606, 1981
PubMed
5) Grimby G, Takishima T, Graham W, Macklem P, Mead J. Frequency dependence of flow resistance in patients with obstructive lung disease. J Clin Invest 47:1455-1465, 1968
PubMed
6) Kjeldgaard JM, Hyde RW, Speers DM, Reichert WW. Frequency dependence of total respiratory resistance in early airway disease. Am Rev Respir Dis 114:501-508, 1976
PubMed
7) Clement J. Landser FJ, Van de Woestijne KP. Total resistance and reactance in patients with respiratory complaints with and without airways obstruction. Chest 83:215-220, 1983
PubMed
8) Cauberghs M. Van de Woestijne KP. Effect of upper airway shunt and series properties on respiratory impedance measurements. J Appl Physiol 66:2274-2279, 1989
PubMed
9) Cauberghs M. Van de Woestijne KP. "Instantaneous" measurements of total respiratory impedance. Eur, Respir Rev 1:226-227, 1991
 
10) Kurosawa H, Kohzuki M. Dynamic airway narrowing. N Engl J Med 350:1036, 2004
PubMed
P.91 掲載の参考文献
1) DuBois AB, Botelho SY, Bedell GN, Marshall R, Comroe JH. A rapid plethysmographic method for measuring thoracic gas volume : A comparison with a nitrogen washout method for functional residual capacity in normal subjects. J Clin Invest 35:322-326, 1956
PubMed
2) DuBois AB, Botelho SY, Comroe JH. A new method for measuring airway resistance in man using a body plethysmograph : Values in normal subjects and in patients with respiratory disease. J Clin Invest 35:327-335, 1956
PubMed
3) Corbeel LJ. Comparison between measurements of functional residual capacity and thoracic gas volume in chronic obstructive pulmonary disease. Progr Resp Res vol 4, Karger. Basel, New York : pp.194-204, 1969
 
4) Brown R, Scharf SM, Ingram RH. Nonhomogeneous alveolar pressure sings in the presence of airway closure. J Appl Physiol : Respir Environ Exercise Physiol 49:398, 1980
 
5) Brown R, Scharf SM, Ingram RH. Nonhomogeneous alveolar pressure sings : effect of different respiratory muscles. J Appl Physiol : Respir Environ Exercise Physiol 52:638, 1982
 
6) Jaeger MJ, Bouhuys A. Loop formation in pressure vs flow diagrams obtained by body plethysmographic techniques. Progr Resp Res vol 4, Karger. Basel, New York : pp.116, 1969
 
7) Jaeger MJ, Otis AB. Mesurement of airway resistance with a volume displacement body plethysmography. J Appl Physol 19:813-820, 1964
 
8) 福永壽晴 大谷信夫 黄正寿 栂博久 寺畑喜朔. 圧型体プレチスモグラフによるpanting法での気道抵抗測定時における温・湿度補正. 呼吸 2:539-545, 1983
 
9) 福永壽晴 大谷信夫 黄正寿 栂博久 寺畑喜朔. 圧型体プレチスモグラフによる安静呼吸時における気道抵抗の連続測定. 呼吸 2:546-552, 1983
 
10) Koulouris NG, Valta P, Lavoie A, Corbeil C, Chasse M, Braidy J, Milic-Emili J. A simple method to detect expiratory flow limitation during spontaneous breathing. Eur Respir J 8:306-313, 1995
PubMed
P.99 掲載の参考文献
1) 日本呼吸器学会肺生理専門委員会「呼吸機能検査ガイドライン」作成委員会. 肺拡散能力検査 : 日本呼吸器学会肺生理専門委員会, 編, 呼吸機能検査ガイドライン-スパイロメトリー, フローボリューム曲線, 肺拡散能力-, 日本呼吸器学会 : pp.26-41, 2004
 
2) American Thoracic Society : Single-breath Carbon Monoxide Diffusing Capacity (Transfer Factor) Recommendations for a Standard Technique-1995 Update. Am J Respir Crit Care Med 152:2185-2198, 1995
PubMed
3) 日本呼吸器学会肺生理専門委員会「呼吸機能検査ガイドライン」作成委員会. 臨床評価 : 日本呼吸器学会肺生理専門委員会, 編, 呼吸機能検査ガイドライン-スパイロメトリー, フローボリューム曲線, 肺拡散能力-, 日本呼吸器学会 : pp.44-53, 2004
 
4) Newth CJL, Cotton DJ, Nadel JA. Pulmonary diffusing capacity measured at multiple intervals during a single exhalation in man. J Appl Physiol 43:617-625, 1977
 
5) Wilson AF, Hearne J, Brenner M, et al. Measurement of transfer factor during constant exhalation. Thorax 4:1121-1126, 1994
 
6) 鈴木勉 吉見格 植木純 福地義之助. 連続呼気採取法(intrabreath法)による肺拡散能の測定. 日呼吸会誌 43:347-353, 2005
 
7) Jones RS, Meade F. A theoretical and experimental analysis of anomalies in the estimation of pulmonary diffusing capacity by the single breath method. Q J Exp Physiol 46:131-143, 1961
PubMed
P.107 掲載の参考文献
1) 日本呼吸器学会肺生理専門委員会, 編. 呼吸機能検査ガイドラインII(血液ガス, パルスオキシメータ), メディカルレビュー社. 東京 : 2006
 
2) 日本呼吸器学会, 編. 臨床呼吸機能検査 第7版. メディカルレビュー社. 東京 : 2008
 
3) Harrison's Principles of Internal Medicine 17th Edition, McGraw-Hill Professional : 2008
 
P.117 掲載の参考文献
1) 寺本信嗣 福地義之助. 運動負荷試験による呼吸不全の評価. Medicial Practice 7:1599-1602, 1999
 
2) ATS/ACCP. ATS/ACCP Statement on Cardiopulmonary Exercise Testing. Am J Respir Crit Care Med 167:211-277, 2003
PubMed
3) McGavin CR, Artvinli M, Naoe H, McHardy GJ. Dyspnoea, disability, and distance walked : comparison of estimates of exercise performance in respiratory disease. Br Med J 2:241-243, 1978
PubMed
4) 瀧島任ほか. 10分間歩行距離法による運動能力の評価. 厚生省特定疾患「呼吸不全」調査研究班. 昭和61年報告書 : pp.104-106, 1984
 
5) ATS Statement. Guidelines for the Six-Minute Walk Test. Am J Respir Crit Care Med 166:111-117, 2002
PubMed
6) Enright PL. The six-minute walk test. Respir Care 48:783-785, 2003
PubMed
7) van Stel HF, Bogaard JM, Rijssenbeek-Nouwens LH, Colland VT. Multivariable assessment of the 6-min walking test in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163:1567-1571, 2001
PubMed
8) Sue DY, Oren A, Hansen JE, Wasserman K. Diffusing capacity for carbon monoxide as a predictor of gas exchange during exercise. N Engl J Med 316:1301-1306, 1987
PubMed
9) Davis JA, Whipp BJ, Lamarra N, Huntsman DJ, Frank MH, Wasserman K. Effect of ramp slope on determination of aerobic parameters from the ramp exercise test. Med Sci Sports Exerc 14:339-343, 1982
PubMed
10) Bruce RA, Merendino KA, Pampush JJ, Sherson E. Quantitative evaluation of mitral commissurotomy by means of a standardized exercise tolerance test. I. Evaluation of method and results. Surgery 36:621-635, 1954
PubMed
11) Bruce RA, Kusumi F, Hosmer D. Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. Am Heart J 85 : 546-562, 1973
PubMed
12) Brunelli A, Fianchini A. Stair climbing test in lung resection candidates with low predicted postoperative FEV1. Chest 124:1179, 2003
PubMed
13) Whipp BJ, Davis JA, Torres F, Wasserman K. A test to determine parameters of aerobic function during exercise. J Appl Physiol 50:217-221, 1981
PubMed
14) Davis JA, Frank MH, Whipp BJ, Wasserman K. Anaerobic threshold alterations caused by endurance training in middle-aged men. J Appl Physiol 46:1039-1046, 1979
 
15) Stevens SS. Neural events and the psychophysical law. Science 170:1043-1050, 1970
PubMed
16) Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14:377-381, 1982
PubMed
17) Aitken RC. Measurement of feelings using visual analogue scales. Proc R Soc Med 62:989-993, 1962
 
18) Teramoto S, Fukuchi Y, Nagase T, Matsuse T, Shindo G, Orimo H. Quantitative assessment of dyspnea during exercise before and after bullectomy for giant bulla. Chest 102:1362-1366, 1992
PubMed
19) Teramoto S, Fukuchi Y, Orimo H. Effects of inhaled anticholinergic drug on dyspnea and gas exchange during exercise in patients with chronic obstructive pulmonary disease. Chest 103:1774-1782, 1993
PubMed
20) O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158:1557-1565, 1998
PubMed
21) O'Donnell DE. Assessment of bronchodilator efficacy in symptomatic COPD : is spirometry useful? Chest 117(Suppl 2):42S-47S, 2000
 
22) Hiraga T, Maekura R, Okuda Y, Okamoto T, Hirotani A, Kitada S, Yoshimura K, Yokota S, Ito M, Ogura T. Prognostic predictors for survival in patients with COPD using cardiopulmonary exercise testing. Clin Physiol Funct Imaging 23:324-331, 2003
PubMed
23) Ram FS, Wedzicha JA. Ambulatory oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2:CD 000238, 2002
 
24) Knower MT, Dunagan DP, Adair NE, Chin R Jr. Baseline oxygen saturation predicts exercise desaturation below prescription threshold in patients with chronic obstructive pulmonary disease. Arch Intern Med 161:732-736, 2001
PubMed
25) Wasserman K. Diagnosing cardiovascular and lung pathophysiology from exercise gas exchange. Chest 112:1091-1101, 1997
PubMed
26) Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, Murray S, Kazerooni EA, Gross BH, Lynch JP 3rd, Martinez FJ. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 168:1084-1090, 2003
PubMed
P.121 掲載の参考文献
1) Cooper KH. A means of assessing maximal oxygen intake. Correlation between field and treadmill testing. JAMA 203:2001-2004, 1968
 
2) Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J 284:1607-1608, 1982
 
3) ATS statement : guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111-117, 2002
PubMed
4) Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 47:1019-1024, 1992
PubMed
5) Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 119:256-270, 2001
 
6) 日本呼吸管理学会, 日本呼吸器学会, 日本理学療法士協会. 呼吸リハビリテーションマニュアル-運動療法一, 照林社. 東京 : pp.76-79, 2003
 
7) Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am Rev Respir Crit Care Med 158:1384-1387, 1998
 
8) Troosters TR, Fruchter N, Sloan S, Levy R. Six minute walking distance in healthy subjects. Eur Respir J 14:270-274, 1999
 
9) Gibbons WJ, Fruchter N, Sloan S, Levy RD. Reference values for a multiple repetition 6-minute walk test in healthy adults older than 20 years. J Cardiopulm Rehabil 21:87-93, 2001
PubMed
10) Camarri B, Eastwood PR, Cecins NM, Thompson PJ, Jenkins S. Six minute walk distance(6 MWD) in healthy subjects aged 55-75 years. Respirology 9:A45, 2004 (Submitted to Respiratory Medicine)
 
11) Poh H, Eastwood PR, Cecins NM, Jenkins S. Six minute walking distance(6 MWD) in healthy Singaporeans aged 45-85 years. Respirolog. 10(Suppl):A58, 2005 (Teramoto S, et al (2000) : Reference value of six-minute waking distance in healthy middle-aged and older subjects. Eur Respir J 15:1132-1133 (letter to the editor), 2005)
 
12) Takishima T. Exercise testing. In : Annual Report of Japanese Respiratory Failure Research Working Group, Ministry of Health, Tokyo : pp.8-13, 1986
 
13) Teramoto S, Ohga E, Ishii T, Yamaguchi Y, Yamamoto H, Mastsuse T. Reference value of six-minute walking distance in healthy middle-aged and older subject. Eur Reapir J 15:1132-1133, 2000
 
14) 千住秀明. 6-minute walking distance : 内山靖 小林武 潮見泰蔵 編, 臨床評価指標入門 適応と解釈のポイント, 共同医書. 東京 : pp.135-141, 2003
 
15) 鋤崎利貴 大城昌平 根地嶋誠 儀間裕貴 河北実保子 千住秀明. 6分間歩行テストの再現性. 理学療法学 31(Suppl):194, 2004
 
16) 高橋哲也. Incremental Shuttle Walking Test(ISWT), 漸増シャトルウォーキングテスト : 内山靖 子林武 潮見泰蔵 編, 臨床評価指標入門 適応と解釈のポイント, 共同医書. 東京 : pp.149-154, 2003
 
17) 有薗信一 高橋哲也 熊丸めぐみ 畦地萠 安達仁 千住秀明 谷口興一. 漸増シャトルウォーキングテストにおける酸素摂取量の直線的増加に関する研究 最高酸素摂取量は総歩行距離から予測可能か? 理学療法学 30:181-185, 2003
 

薬物療法

P.129 掲載の参考文献
1) 久米裕昭 杉下美保子 宮嶋宏之ほか. β2刺激薬の固有活性とそれに基づく臨床投与の実際. アレルギー・免疫 16(10):1604-1614, 2009
 
2) Yamaya M, Nishimura H, Hatachi Y, et al. Procaterol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Eur J Pharmacol 650(1):431-444, 2011
PubMed
3) 中張隆司 大黒恵理子 島本史夫. 気道線毛の機能と病態. 呼吸と循環 59(1):57-65, 2011
 
4) 田中康正 田中裕士. プロカテロールドライパウダー. 呼吸 24(12):1027-1033, 2005
Medical*Online
5) Brock TP, Wessell AM, Williams DM, et al. Accuracy of float testing for metered-dose inhaler canisters. J Am Pharm Assoc (Wash) 42(4):582-586, 2002
PubMed
6) Sander N, Fusco-Walkert SJ, Harder JM, et al. Dose counting and the use of pressurized metered-dose inhalers : running on empty. Ann Allergy Asthma Immunol 97(1):34-38, 2006
PubMed
7) 向佳世 小野山真一郎 西島政洋ほか. 携帯用定量式噴霧器(MDI)の残量調査と残量チェック方法の検討. 薬事 34(10):2155-2158, 1992
 
8) Integration of Dose-Counting Mechanisms into MDI Drug Product. Journal : 2003
 
9) 堀口高彦 近藤りえ子 伴直昭ほか. 高齢者喘息の特徴を考慮した治療ナビゲーション 吸入薬の手技確認と理解度に関する検討. アレルギー・免疫 17(6):1086-1093, 2010
 
10) Suissa S, Hemmelgarn B, Blais L, et al. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med 154(6 Pt 1):1598-1602, 1996
 
11) Paris J, Peterson EL, Wells K, et al. Relationship between recent short-acting beta-agonist use and subsequent asthma exacerbations. Ann. Allergy, Asthma Immunol 101(5):482-487, 2008
PubMed
12) 堀江健夫 矢冨正清 遠藤克明ほか. 【地域連携パス 現況と今後の課題】救急医療と地域連携パス. 医薬ジャーナル 44(8):104-110, 2008
 
13) Newhouse MT, Nantel NP, Chambers CB, et al. Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates. Chest 115(4):952-956, 1999
PubMed
14) 一ノ瀬正和 相澤久道 石坂彰敏ほか. 日本における慢性閉塞性肺疾患(COPD)患者の大規模電話実態調査 Confronting COPD Japan Survery. 日本呼吸器学会雑誌 45(12):927-935, 2007
 
15) 佐藤英夫 岩島明 遠藤禎郎ほか. 慢性閉塞性肺疾患の日常生活動作の息切れとQOLに対するプロカテロールの効果. 日本呼吸器学会雑誌 47(9):772-780, 2009
Medical*Online
16) 堀江健夫 滝瀬淳 稲澤正士ほか. 地域で育むCOPDマネジメント 疾病管理体制の確立へ向けた地域連携パスの活用. 日本呼吸ケア・リハビリテーション学会誌 18(1):18-23, 2008
 
17) 長谷川信 土橋邦生 千木良佑介ほか. COPDに対する短時間作用型β2刺激薬併用の運動療法効果について. 日本呼吸ケア・リハビリテーション学会誌 18(Suppl):141s, 2008
 
18) Shioya T, Satake M, Sato K, et al. Long-term effect of the beta2-receptor agonist procaterol on daily life performance and exercise capacity in patients with stable chronic obstructive pulmonary disease. Clinical study with special reference to health-related quality of life and activities of daily living. Arzneimittelforschung 58(1):24-28, 2008
PubMed
19) Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease : a systematic review of the literature. Health Technol Assess 5(26):1-149, 2001
PubMed
20) van der Palen J, Klein J, van Herwaarden C, et al. Multiple inhalers confuse asthma patients. Eur Respir J 14(5):1034-1037, 1999
PubMed
21) Bosnic-Anticevich SZ, Sinha H, So S, et al. Metered-dose inhaler technique : the effect of two educational interventions delivered in community pharmacy over time. J Asthma 47(3):251-256, 2010
PubMed
P.133 掲載の参考文献
1) Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (Available at www.goldcopd.com)
 
2) 日本呼吸器学会COPDガイドライン第2版作成委員会, 編, COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン 第2版. メディカルレビュー社. 東京 : 2009
 
3) O'Donnell DE, Lam M. Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:542-549, 1999
PubMed
4) Niewoehner DE. Structure-function relationships : the pathophysiology of airflow obstruction. In : Stockley R, et al, eds. Chronic obstructive pulmonary disease, Blackwell Publishing : pp.63-74, 2007
 
5) Donohue JF, van Noord JA, Bateman ED. Langley SJ, Lee A, Witek TJ Jr. Kesten S. Towse L. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122 : 47-55, 2002
PubMed
6) Tashkin DP. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359:1543-1554, 2008
PubMed
7) Celli BR, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 178:332-338, 2008
PubMed
8) Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:775-789, 2007
PubMed
9) Pitta FP, Troosters T, Spruit MA, et al. Activity monitoring for assessment of physical activities in daily life in patients with chronic obstructive pulmonary disease. Arc Phys Med Rehabil 86:1979-1985, 2005
 
10) Pitta FP, Troosters T, Spruit MA et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171:972-977, 2005
 
11) COPD診療マニュアル, 一ノ瀬正和, 編. 南江堂. 東京 : 2005
 
12) COPDのすべて, 永井厚志 一ノ瀬正和, 編. 文光堂. 東京 : 2008
 
P.139 掲載の参考文献
1) Naline E, Zhang Y, Qian Y, Mairon N, Anderson GP, Grandordy B, Advenier C. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur Respir J 7:914-920, 1994
 
2) Brittain RT. Approaches to a long-acting, selective beta 2-adrenoceptor stimulant. Lung 168:111-114, 1990
PubMed
3) Johnson M, Butchers R, Nialis A, Strong P, Vardey C, Whelan C. The pharmacology of salmeterol. Life Sci 52:2131-2143, 1993
 
4) Jeppsson AB, Lofdahl CG, Waldeck B, Widmark E. On the predictive value of experiments in vitro in the evaluation of the effect duration of bronchodilator drugs for local administration. Pulm Pharmacol 2:81-85, 1989
PubMed
5) Lofdahl CG. Basic pharmacology of new long-acting sympathomimetics. Lung 168(Suppl):18-21, 1990
 
6) Ball DI, Brittain RT, Coleman RA, Denyer LH, Jack D, Johnson M, Lunts LH, Nials AT, Sheldrick KE, Skidmore IF. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist : characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol 104:665-671, 1991
PubMed
7) Arvidsson P, Larsson S, Lofdahl B, Melander B, Wahlander L, Svedmyr N. Formoterol, a new long acting bronchodilator for inhalation. Eur Respir J 2:325 330, 1989
 
8) Ullman A, Svedmyr N, Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist : comparison with salbutamol in adult asthmatic patients. Thorax 43:674-678, 1988
PubMed
9) Ullman A, Hedner J, Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachy-phylaxis. Am Rev Respir Dis 142:571-575, 1990
 
10) Rabe K, Jorres R, Nowak D, Behr N, Magnussen H. Comparisson of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 147:1436-1441, 1993
 
11) Lofdahl CG, Chung KF. Long-acting beta 2-adrenoceptor agonists : a new perspective in the treatment of asthma. Eur Respir J 4:218-226, 1991
PubMed
12) Johnson M. Beta 2-agonists as anti-inflammatory therapies in the lung. Agents Actions Actions 41(Suppl):27-45, 1993
PubMed
13) Butchers PR, Vardey CJ, Johnson M. Salmeterol : a potent and long-acting inhibitor of inflammatory mediator release from human lung. Br J Pharmacol 104:672-676, 1991
 
14) Whelan CJ, Johnson M. Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin. Br J Pharmacol 105:831-838, 1992
PubMed
15) Baluk P, McDonald DM. The beta 2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. Am J Physiol 266:L461-L468, 1994
PubMed
16) Bloemen PG, van den Tweel MC, Henricks PA, Engels F, Kester MH, van de Loo PG, Blomjous FJ, Nijkamp FP. Increased cAMP levels in stimulated neutrophils inhibit their adhesion to human bronchial epithelial cells. Am J Physiol 272:L580-L587, 1997
PubMed
17) Anderson R, Feldman C, Theron AJ, Ramafi G, Cole PJ, Wilson R. Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro. Br J Pharmacol 117:1387-1394, 1996
PubMed
18) Johnson M, Rennard S. Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD. Chest 120:258-270, 2001
PubMed
19) Rusnak C, Spasford R, Devalia J, Davies R. Effect of salbutamol and salmeterol on the ciliary beat frequency (CBF) of human bronchial epithelium in vitro. Am Rev Respir Dis 141:A1030, 1990
 
20) Twentyman OP, Finnerty JP, Harris A, Palmer J, Holgate ST. Protection against allergen-induced asthma by salmeterol. Lancet 336:1338-1342, 1990
PubMed
21) Gardiner P, Ward C, Booth H, Allison A, Hendrick D, Walters EH. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 150:1006-1011, 1994
PubMed
22) Dahl R, Peders B. The influence of inhaled salmeterol on bronchial inflammation. A broncho-alveolar lavage study in patients with bronchial asthma. Eur Respir J 1:272-275, 1991
 
23) Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta 2-agonists and corticosteroids. Eur Respir J 19:182-191, 2002
 
24) Kips JC, Pauwels RA. Long-acting inhaled beta(2)-agonist therapy in asthma. Am J Respir Crit Care Med 164:923-932, 2001
PubMed
25) Eickelberg O, Roth M, Lorx R, Bruce V, Rudiger J, Johnson M, Block LH. Ligand-independent activation of the glucocorticoid receptor by beta 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 274:1005-1010, 1999
 
26) Dahl R, Earnshaw JS, Palmer JB. Salmeterol : a four week study of a long acting beta-adrenoceptor agonist for the treatment of reversible airways disease. Eur Respir J 4:1178-1184, 1991
PubMed
27) Arvidsson P, Larsson S, Lofdahl CG, Melander B, Svedmyr N, Wahlander L. Inhaled formoterol during one year in asthma : a comparison with salbutamol. Eur Respir J 4:1168-1173, 1991
PubMed
28) Vathenen A, Knox A, Higgins B, Britton J, Tattersfield A. Rebound increase in bronchial responsiveness with inhaled terbutaline. Lancet i:554-557, 1988
PubMed
29) Bronsky EA, Kemp JP, Orgel HA, Bierman CW, Tinkel-man DG, van As A, Liddle RF. A 1-week dose-ranging study of inhaled salmeterol in patients with asthma. Chest 105:1032-1037, 1994
 
30) D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma [see comments]. JAMA 271:1412-1416, 1994
 
31) Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 157:S1-53, 1998
PubMed
32) Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, Knobil K. Fluticasone propionate/salmeterol combination provides more effective asthma control than low dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 106:1088-1095, 2000
PubMed
33) Davies B, Brooks G, Devoy M. The efficacy and safety of salmeterol compared to theophylline : meta-analysis of nine controlled studies. Respir Med 92:256-263, 1998
PubMed
34) WHO/NIH. Global Initiative for Asthma : 2002
 
35) Kips JC, O'Connor BJ, Inman MD, Svensson K, Pauwels RA, O'Byrne PM. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 161:996-1001, 2000
PubMed
36) NHLBI/WHO Workshop Report. Global Initiative for Obstructive Lung Disease : 2003
 
37) Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 115:957-965, 1999
PubMed
38) Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease(COPD). Eur Respir J 10 : 815-821, 1997
PubMed
39) Taccola M, Bancalari L, Ghignoni G, Paggiaro PL. Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease. Monaldi Arch Chest Dis 54:302-306, 1999
PubMed
40) van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 15:878-885, 2000
PubMed
41) ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, Knobil K. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 119:1661-1670, 2001
PubMed
42) Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C, Trial of Inhaled Steroids and long-acting beta 2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease : a randomised controlled trial. Lancet 361:449-456, 2003
 
P.149 掲載の参考文献
1) 日本アレルギー学会喘息ガイドライン専門部会, 編, 喘息予防・管理ガイドライン2006, 協和企画. 東京 : 2006
 
2) Tamura G, Sano Y, Hirata K, Ishioka S, Nakashima M, Miyamoto T. Effect of Transdermal Tulobuterol Added to Inhaled Corticosteroids in Asthma Patients. Allergol Int 54:615-620, 2005
 
3) Kume H. Clinical Use of β2-adrenergic Receptor Agonists Based on Their Intrinsic Efficacy. Allergol Int 54:89-97, 2005
 
4) 堀口高彦 近藤りえ子 宮崎淳一 鳥越寛史 立川壮一. 成人気管支喘息患者におけるツロブテロール貼付薬連用による気道炎症および気道過敏性の推移. 日呼吸会誌 42:132-137, 2004
 
5) NHLBI WHO Workshop Report : Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Update 2003
 
6) 日本呼吸器学会COPDガイドライン第2版作成委員会, 編, COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン第2版, メディカルレビュー社. 東京 : 2004
 
7) 石岡伸一 保澤総一郎 木村俊樹ほか. 経皮吸収型気管支拡張剤HN-078(ツロブテロールテープ)の慢性閉塞性肺疾患(慢性気管支炎, 肺気腫)に対する臨床効果. Therapeutic Reaearch 16:1449-1462, 1995
 
8) 三浦傳 塩谷隆信 三浦一樹ほか. 慢性気管支炎および肺気腫に対するHN-078の臨床効果. 新薬と臨床 44:589-601, 1995
 
9) 山本和英 青木茂 内田淳夫ほか. 慢性閉塞性肺疾患に関するHN-078の臨床的検討肺気腫を中心に. 診療と新薬 32:815-823, 1995
 
10) 池田英樹. 慢性気管支炎, 肺気腫などの慢性閉塞性肺疾患に対するHN-078の臨床効果. 診療と新薬 32:824-833, 1995
 
11) 平田一人. β2刺激薬貼付剤の位置づけ. 呼吸器科 1:255-259, 2002
 
12) Eguchi Y, Hirata K, Nomura N, et al. Clinical Long-term efficacy of tulobuterol patch (Long acting β2-agonist) in patients with COPD. Proceeding of the American Thoracic Society 2005. A 543 (abstract)
 
13) van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 129:509-517, 2006
PubMed
14) van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJ. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 26:214-222, 2005
PubMed
15) Fukuchi Y, Nagai A, Seyama K, Nishimura M, Hirata K, Kubo K, Ichinose M, Aizawa H and BAREC Research Group. Clinical efficacy and safety of transdermal tulobuterol in the treatment of stable COPD : an open-label comparison with inhaled salmeterol Treat Respir Med 4:447-455, 2005
 
P.155 掲載の参考文献
1) Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease updated 2003 eds. National Institutes of Health, National Heart, Lung, and Blood Institute : 2003
 
2) Barnes PJ. The pharmacological properties of tiotropium. Chest 117:63S-66S, 2000
PubMed
3) Gross NJ. Anticholinergic drugs. In : Barnes PJ, Grunstein MM, Leff AR, Woolcock AJ, eds. Asthma, Lippincott-Raven Press. Philadelphia : pp1555-1568, 1997
 
4) Takahashi T, et al. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 150:1640-1645, 1994
PubMed
5) Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci 52:521-527, 1993
PubMed
6) Eglen RM, et al. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 48:531-565, 1996
PubMed
7) Disse B, et al. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci 52:537-544, 1993
PubMed
8) Haddad EB, et al. Characterization of [3H] Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung : radioligand binding and autoradiographic mapping. Mol Pharmacol 45:899-907, 1994
PubMed
9) Disse B, et al. Tiotropium (Spiriva) : mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 64:457-464, 1999
PubMed
10) O'Connor BJ, et al. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 154:876-880, 1996
PubMed
11) Maesen FP, et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator : a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J 8:1506-1513, 1995
 
12) Littner MR, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 61:1136-1142, 2000
 
13) Casaburi R, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19:217-224, 2002
 
14) Casaburi R, et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD : a 13-week multicenter trial. The US Tiotropium Study Group. Chest 118:1294-1302, 2000
 
15) van Noord JA, et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 55:289-294, 2000
 
16) Vincken W, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 19:209-216, 2002
 
17) Donohue JF, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122:47-55, 2002
PubMed
18) Brusasco V, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58:399-404, 2003
PubMed
P.162 掲載の参考文献
1) Tashkin DP. Celli B. Decramer M. et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 31:742-750, 2008
PubMed
2) Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:775-789, 2007
PubMed
3) Tashkin DP, Celli B. Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359:1543-1554, 2008
PubMed
4) Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Bethesda, MD : National Heart, Lung, and Blood Institute, updated 2008 (available at http://www.goldcopd.org.)
 
5) Takahashi T. Ichinose M. Inoue H, et al. Underdiagnosis and undertreatment of COPD in primary care settings. Respirology 8:504-508, 2003
PubMed
6) Akamatsu K. Yamagata T. Kida Y. Tanaka H. Ueda H. Ichinose M. Poor Sensitivity of Symptoms in Early Detection of COPD. J COPD 5:269-273, 2008
 
7) 日本呼吸器学会COPDガイドライン第3版作成委員会. COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン(第3版), メディカルレビュー社 : 2009
 
8) 小荒井晃 一ノ瀬正和. 長時間作用型抗コリン薬 : 永井厚志 一ノ瀬正和, 編, COPDのすべて, 文光堂 : pp195-199, 2008
 
9) Barnes PJ. The Pharmacological Properties of Tiotropium. Chest 117:63S-66, 2000
PubMed
10) Takahashi T, et al. Effect of Ba679BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 150:1640-1645, 1994
 
11) Donohue JF, et al. A 6-Month, Placebo-Controlled Study Comparing Lung Function and Health Status Changes in COPD Patients Treated With Tiotropium or Salmeterol. Chest 122:47-55, 2002
PubMed
12) Celli B, et al. Improvement in Resting Inspiratory Capacity and Hyperinflation With Tiotropium in COPD Patients With Increased Static Lung Volumes. Chest 124:1743-1748, 2003
PubMed
13) O'Donnell DE, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23:832-840, 2004
PubMed
14) Celli BR, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 178:332-338, 2008
PubMed
15) Miravitlles M, Anzueto A. Insights into interventions in managing COPD patients : lessons from the TORCH and UPLIFT studies. Int J COPD 4:185-201, 2009
 
16) Decramer M, Celli B, Kesten S, et al. Effects of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT) : a prespecified subgroup analysis of a radomised controlled trial. Lancet 374:1171-1178, 2009
 
17) Hochrainer D, Holz H, Kreher C, et al. Comparison of the aerosol velocity and spray duration of Respimat(R) Soft Mist(TM) Inhaler and pressurized metered dose inhalers. J Aerosol Med 18:273-282, 2005
 
18) 一ノ瀬正和. 新規デバイス : COPD治療薬チオトロピウムレスピマット. PharmaMedica 28:83-89, 2010
 
19) Brand P, Hederer B, Austen G, et al. Higher lung deposition with Respimat(R) Soft Mist(TM) Inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis 3:763-770, 2008
 
20) Caillaud D, Le Merre C, Martinat Y, et al. A dose-ranging study of tiotropium delivered via Respimat(R) Soft Mist(TM) Inhaler or HandiHaler(R) in COPD patients. Int J Chorn Obstruct Pulmon Dis 2:559-565, 2007
 
21) van Noord JA. Cornelissen PJG, Aumann J-L, et al. The efficacy of tiotropium administered via Respimat(R) Soft Mist(TM) Inhaler or HandiHaler(R) in COPD patients. Respir Med 103:22-29, 2009
 
22) Ichinose M. Fujimoto T. Fukuchi Y. Tiotropium 5μg via Respimat and 18μg via Handihaler ; efficacy and safety in Japanese COPD patients. Respir Med 104:228-236, 2010
 
P.169 掲載の参考文献
1) Baraniuk JN, Ali M, Brody D, Maniscalco J, Gaumond E, Fitzgerald T, Wong G, Yuta A, Mak JC, Barnes PJ, Bascom R, Troost T. Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med 155:704-710, 1997
PubMed
2) Orsida BE. Ward C, Li X, Bish R, Wilson JW, Thien F, Walters EH. Effect of a long-acting beta2-agonist over three months on airway wall vascular remodeling in asthma. Am J Respir Crit Care Med 164:117-121. 2001
PubMed
3) Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 157:S1-53, 1998
PubMed
4) Greening AP, Ind PW. Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 344:219-224, 1994
 
5) Li X. Ward C, Thien F. et al. An antiinflammatory effect of salmeterol, a long-acting beta2 agonist. assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 160:1493-1499, 1999
PubMed
6) Wallin A, Sue-Chu M, Bjermer L, et al. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. J Allergy Clin Immunol 112:72-78, 2003
PubMed
7) van den Toorn LM, Prins J-B. de Jongste JC, et al. Benefit from anti-inflammatory treatment during clinical remission of atopic asthma. Respir Med 99(6):779-787. 2005
PubMed
8) Lundback B, Ronmark E, Lindberg A, et al. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir Med 100:2-10. 2006
PubMed
9) Currie GP. Stenback S, Lipworth BJ. Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. Br J Clin Pharmacol 56:11-17, 2003
PubMed
10) Fowler SJ, Currie GP, Lipworth BJ. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone. J Allergy Clin Immunol 109:929-935, 2002
PubMed
11) Masoli M Weatherall M Holt S, et al. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 60:730-734, 2005
PubMed
12) Bergmann K-C, Lindemann L, Braun R, et al. Salmeterol/fluticasone propionate (50/250 mug) combination is superior to double dose fluticasone (500 mug) for the treatment of symptomatic moderate asthma : A prospective, double-blind trial. Swiss Med Wkly 134:50-58, 2004
 
13) Jenkins C, Woolcock AJ, Saarelainen P, et al. Salmeterol/fluticasone propionate combination therapy 50/250 mug twice daily is more effective than budesonide 800 mug twice daily in treating moderate to severe asthma. Respir Med 94:715-723, 2000
 
14) Lundback B, Jenkins C, Price MJ, et al. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 mug twice daily and budesonide 800 mug twice daily in the treatment of adults and adolescents with asthma. Respir Med 94:724-732, 2000
 
15) Fowler SJ, Currie GP, Lipworth BJ. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone. J Allergy Clin Immunol 109:929-935, 2002
PubMed
16) Busse W, Koenig SM, Oppenheimer J, et al. Steroid-sparing effects of fluticasone propionate 100 mug and salmeterol 50 mug administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 mug administered twice daily. J Allergy Clin Immunol 111:57-65, 2003
 
17) Bateman ED. Boushey HA, Bousquet J, Busse WW. Clark TJ, Pauwels RA, Pedersen SE : GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 170:836-844, 2004
PubMed
18) Stempel DA, Stoloff SW. Rosenzweig JRC, et al. Adherence to asthma controller medication regimens. Respir Med 99:1263-1267, 2005
 
19) Bateman ED, Britton M, Carrillo J. et al. Salmeterol/fluticasone combination inhaler. A new, effective and well tolerated treatment for asthma. Clin Drug Invest 16:193-201, 1998
 
20) Chapman KR, Ringdal N, Backer V, et al. Salmeterol and fluticasone propionate (50/250 mug) administered via combination Diskus inhaler : As effective as when given via separate Diskus inhalers. Can Respir J 6:45-51, 1999
 
21) Nelson HS, Chapman KR, Pyke SD, et al. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 112:29-36, 2003
PubMed
22) Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 115:957-965, 1999
PubMed
23) Pauwels R, Lofdahl C-G, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 340:1948-1953, 1999
PubMed
24) Vestbo J, Sorenson T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease : a randomised controlled trial. Lancet 353:1819-1823, 1999
 
25) Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease : the ISOLDE trial. BMJ 320:1297-1303, 2000
 
26) The lung health study research group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 343:1902-1909, 2000
 
27) Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166(8):1084-1091, 2002
PubMed
28) Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 21:68-73, 2003
PubMed
29) Calverley P, Pauwels R. Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease : a randomised controlled trial. Lancet 361:449-456. 2003
PubMed
30) Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21:74-81, 2003
PubMed
31) Rutgers SR, Postma DS, ten Hacken NH, Kauffman HF. van Der Mark TW. Koeter GH, Timens W. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 55:12-18, 2000
PubMed
32) Hodge S, Hodge G, Holmes M, Reynolds PN. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J 25:447-454, 2005
 
33) Domagala-Kulawik J, Maskey-Warzechowska M, Kraszewska I, Chazan R. The cellular composition and macrophage phenotype in induced sputum in smokers and ex-smokers with COPD. Chest 123:1054-1059, 2003
PubMed
34) Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 173:736-743, 2006
PubMed
35) Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C. Jones PW. Yates JC, Vestbo J ; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:775-789, 2007
PubMed
P.178 掲載の参考文献
1) Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 343(8904):1006-1008, 1994
PubMed
2) Aizawa H, Iwanaga T, Inoue H, Takata S, Matsumoto K, Takahashi N, et al. Once-daily theophylline reduces serum eosinophil cationic protein and eosinophil levels in induced sputum of asthmatics. Int Arch Allergy Immunol 121(2):123-128, 2000
PubMed
3) Lim S, Tomita K, Caramori G, Jatakanon A, Oliver B, Keller A, et al. Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med 164(2):273-276, 2001
 
4) Baba K, Sakakibara A, Yagi T, Niwa S, Hattori T, Koishikawa I, et al. Effects of theophylline withdrawal in well-controlled asthmatics treated with inhaled corticosteroid. J Asthma 38(8):615-624, 2001
PubMed
5) Minoguchi K, Kohno Y, Oda N, Wada K, Miyamoto M, Yokoe T, et al. Effect of theophylline withdrawal on airway inflammation in asthma. Clin Exp Allergy 28(Suppl 3):57-63, 1998
 
6) Lim S, Jatakanon A, Gordon D, Macdonald C, Chung KF, Barnes PJ. Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice. Thorax 55(10):837-841, 2000
PubMed
7) Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 337(20):1412-1418, 1997
PubMed
8) Deguchi M, To Y, Ito M, Adcock I, Barnes PJ, Ito K. Low dose theophylline restores steroid insensitivity in PBMCs of steroid resistant asthmatics. Eur Respir J (Suppl) : 2004
 
9) Culpitt SV, De Matos C, Russell RE, Donnelly LE, Rogers DF, Barnes PJ. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 165(10):1371-1376, 2002
PubMed
10) Kobayashi M, Nasuhara Y, Betsuyaku T, Shibuya E, Tanino Y, Tanino M, et al. Effect of low-dose theophylline on airway inflammation in COPD. Respirology 9(2):249-254, 2004
PubMed
11) Kirsten DK, Wegner RE, Jorres RA, Magnussen H. Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease. Chest 104(4):1101-1107, 1993
PubMed
12) ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 119(6):1661-1670, 2001
PubMed
13) To Y, Kharitonov SA, Adcock I, Barnes PJ, Ito K. Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline. Eur Respir J (Suppl) : 2005
 
14) Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 63(23):2575-2594, 2003
PubMed
15) Vignola AM. PDE 4 inhibitors in COPD-a more selective approach to treatment. Respir Med 98(6):495-503, 2004
PubMed
16) Rorke S, Holgate ST. Targeting adenosine receptors : novel therapeutic targets in asthma and chronic obstructive pulmonary disease. Am J Respir Med 1(2):99-105, 2002
PubMed
17) Foukas LC, Daniele N, Ktori C, Anderson KE, Jensen J, Shepherd PR. Direct effects of caffeine and theophylline on p 110 delta and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities. J Biol Chem 277(40):37124-37130, 2002
 
18) Ohta K, Sawamoto S, Nakajima M, Kubota S, Tanaka Y, Miyasaka T, et al. The prolonged survival of human eosinophils with interleukin-5 and its inhibition by theophylline via apoptosis. Clin Exp Allergy 26(Suppl 2):10-15, 1996
 
19) Yao PL, Tsai MF, Lin YC, Wang CH, Liao WY, Chen JJ, et al. Global expression profiling of theophylline response genes in macrophages : evidence of airway anti-inflammatory regulation. Respir Res 6:89, 2005
PubMed
20) Barnes PJ. Theophylline in chronic obstructive pulmonary disease : new horizons. Proc Am Thorac Soc 2(4):334-339, 2005
PubMed
21) Moonen HJ, Geraets L, Vaarhorst A, Bast A, Wouters EF, Hageman GJ. Theophylline prevents NAD(+) depletion via PARP-1 inhibition in human pulmonary epithelial cells. Biochem Biophys Res Commun 338(4):1805-1810, 2005
PubMed
22) Cho KS, Elizondo LI, Boerkoel CF. Advances in chromatin remodeling and human disease. Curr Opin Genet Dev 14(3):308-315, 2004
PubMed
23) Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation : importance in inflammatory lung diseases. Eur Respir J 25(3):552-563, 2005
PubMed
24) Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 15(6):1110-1112, 2001
PubMed
25) Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 352(19):1967-1976, 2005
 
26) Ito K, Caramori G, Lim S, Oates T, Chung KF, Barnes PJ, et al. Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med 166(3):392-396, 2002
PubMed
27) Ito K, Yamamura S, Essisifie-Quay S, Cosio B, Ito M, Barnes PJ, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-B suppression. J Exp Med 2005 (in press)
 
28) Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 200(5):689-695, 2004
PubMed
29) Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, et al. A molecular mechanism of action of theophylline : Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 99(13):8921-8926, 2002
PubMed
P.184 掲載の参考文献
1) 阿部眞弓. 禁煙指導法. 日呼吸会誌 42:607-615, 2004
Medical*Online
2) Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking Cessation and Lung Function in Mild-to-Moderate Chronic Obstructive Pulmonary Disease : The Lung Health Study. Am J Respir Crit Care Med 161:381-390. 2000
PubMed
3) Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950 : combination of national statistics with two case-control studies. BMJ 321:323-329, 2000
PubMed
4) Kleinman JC, Pierre MB Jr, Madans JH, Land GH, Schramm WF. The effects of maternal smoking on fetal and infant mortality. Am J Epidiol 127:274-282, 1988
 
5) Pell JP, Haw S, Cobbe S, Newby DE, Pell AC, Fischbacher C, McConnachie A, Pringle S, Murdoch D, Dunn F, Oldroyd K, Macintyre P, O'Rourke B, Borland W. Smoke-free Legislation and Hospitalizations for Acute Coronary Syndrome. NEJM 359:482-491, 2008
PubMed
6) U.S. Department of Health and Human Services. Clinical Practice Guideline Treating Tobacco Use and Dependence : 2008 Update
 
7) 日本循環器学会, 日本肺癌学会, 日本癌学会. 禁煙治療のための標準手順書 第3版 : 2008
 
8) Corrigall WA. Franklin KB. Coen KM, Clarke PBS. The mesolimbic dopaminergic system is implicated in the reinforcement effects of nicotine. Psychopharmacol (Berl) 107:285-289, 1992
 
9) Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE. Rationale, Pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation. Trends Pharmacol Sci 28:316-325, 2007
 
10) α4β2ニコチン受容体部分作動薬(禁煙補助薬) チャンピックス(R)錠 医薬品インタビューフォーム 第4版 : 2008年9月
 
11) Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, William KE, Billing CB, Gong J, Reeves KR. Efficacy of Valenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial. JAMA 296:56-63, 2006
 
12) Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR. Valenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation A Randomized Controlled Trial. JAMA 296:47-55, 2006
 
13) Aubin HJ. Bobak A, Britton JR, Oncken C, Billing CB, Gong J, Williams KE, Reeves KR. Varenicline versus transdermal nicotine patch for smoking cessation : Results from a randomised, open-label trial. Thorax. 63:717-724, 2008
PubMed
14) Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 16 : CD006103, 2008
 
15) Michael O'Riordan. FDA approves varenicline for smoking cessation. May 12:2006 (http://www.theheart.org/article/698453.do. 2008年10月1日アクセス)
 
16) 磯村毅 リセット禁煙のすすめ, 東京六法. 東京 : 2004
 
17) 加濃正人. ニコチンの心理的依存. 日ア精医誌 15:3-14, 2008
 
18) 吉井千春. ニコチン依存度テストの現在と未来(TDS, FTND, KTSND). 治療 88:2572-2575, 2006
Medical*Online
19) クリスティーナ・イヴィングス. 喫煙の心理学. 産調出版. 東京 : 2007
 
20) α4β2ニコチン受容体部分作動薬(禁煙補助薬) チャンピックス(R) 新医薬品の「使用上の注意」の解説 : 2008年1月
 
21) 川根博司. コールド・ターキー. 医事新報 3616:59-60, 1993
 
22) α4β2ニコチン受容体部分作動薬(禁煙補助薬) チャンピックス(R)錠添付文書. 第3版 : 2008年7月
 
23) Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and Tolerability of Vaernicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, in a 12-Week, Randomized, Placebo-Controlled, Dose-Response Study with 40-Week Follow-Up for Smoking Cessation in Japanese Smokers. Clin Ther 29:1040-1056. 2007
 
24) 作田学. バレニクリン(チャンピックス(TM) ) の有害事象について. 禁煙会誌 3:22-25, 2008
Medical*Online
25) Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl. Acad Sci USA 104:12518-12523, 2007
PubMed
26) Stoops WW, Vansickel AR, Glaser PE, Rush CR. The influence of acute varenicline administration on smoking and eating behavior in humans. Pharmacol Biochem Behav 91:165-169, 2008
PubMed

非薬物療法

P.199 掲載の参考文献
1) 塩谷隆信. 包括的呼吸リハビリテーションの現状と展望. 日内会誌 99(3):136-143, 2010
 
2) American Thoracic Society, European Respiratory Society. ATS/ERS statement on pulmonary rehabilitation. Am Rev Crit Care Med 173:1390-1413, 2006
 
3) Ries AL. Bauldoff GS, Carlin BW, et al. Pulmonary Rehabilitation : Joint ACCP/AACVPR Evidence-Based Clinical Practical Guidelines. Chest 131:4S-42S, 2007
PubMed
4) 日本呼吸器学会, 日本呼吸器学会COPDガイドライン第3版作成委員会. COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン 第3版. メディカルレビュー社. 東京 : 2009
 
5) 塩谷隆信. 包括的呼吸リハビリテーションとは : 高橋仁美 宮川哲夫 塩谷隆信, 編, 動画でわかる呼吸リハビリテーション(改訂版). 中山書店 : pp2-9. 2008
 
6) 日本呼吸ケア・リハビリ学会, 日本呼吸器学会, 日本リハビリ医学会. 日本理学療法士協会, 編, 呼吸リハビリテーションマニュアル-患者教育の考えかたと実践-. 照林社. 東京 : 2007
 
7) Pitta F. Troosters T, Spruit MA, et al. Characteristics of physical activities in daily life in chronic obstructive disease. Am J Respir Crit Care Med 171:972-977, 2005
PubMed
8) Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease : a population based cohort study. Thorax 61:772-778, 2006
PubMed
9) American Thoracic Society. Dyspnea : mechanism, assessment, and management. A consensus statement. Am J Respir Crit Care Med 159:321-340, 1999
PubMed
10) Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 127:809-817, 2005
PubMed
11) 日本呼吸ケア・リハビリ学会, 日本呼吸器学会, 日本リハビリ医学会, 日本理学療法士協会, 編, 呼吸リハビリテーションマニュアル-運動療法-第2版, 照林社. 東京 : 2010 (発行予定)
 
12) 高橋仁美 菅原慶勇 佐竹將宏ほか. 座ってできるCOPD体操. 呼吸器科 11:291-301, 2007
 
13) 塩谷隆信, 佐竹將宏 高橋仁美ほか. 安定期COPD患者における低強度呼吸リハビリテーションの有用性. 呼吸 25(3):311-330, 2006
Medical*Online
14) Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. Bethesda, National Heart. Lung and Blood Institute, April 2001 ; Update of the Management Sections, GOLD website (www.goldcopd.com), updated : December 2009
 
15) Celli BR, Cote CG, Martin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350:1005-1012, 2004
 
16) 塩谷隆信 佐竹將宏 玉木彰ほか. COPDにおける運動療法-栄養療法との関連を中心に-. 臨床栄養 114(3):278-285, 2009
Medical*Online
17) 菅原慶勇 高橋仁美 清川憲孝ほか. 安定期慢性閉塞性肺疾患患者における栄養障害と全身性炎症について. 日呼ケアリハ学誌 18(2):177-181, 2008
 
18) Oga T, Nishimura K, Tsukino M, et al. Analysis of factors related to mortality in chronic obstructive pulmonary disease. Role of exercise capacity and health status. Am J Respir Crit Care Med 167:544-549, 2002
PubMed
19) Puhan MA, Schunemann HJ, Frey M, et al. How should COPD patients exercise during respiratory rehabilitation? Comparison of exercise modalities and intensities to treat skeletal muscle dysfunction. Thorax 60:367-375, 2005
PubMed
20) Beauchamp MK, Nonoyama M, Goldstein RS, et al. Interval versus continuous training in individuals with chronic obstructive pulmonary disease- a systematic review. Thorax 65:157-164, 2010
PubMed
21) Puhan MA, Schunemann HJ, Frey M, et al. Value of supplemental interventions to enhance the effectiveness of physical exercise during respiratory rehabilitation in COPD patients. A systemtic review. Respir Res 5:25, 2004
 
22) 塩谷隆信 佐竹將宏 玉木彰ほか. 呼吸筋トレーニングの有用性に関するシステマティック・レビュー. 日呼ケアリハ学誌 1(Suppl):p199s, 2009
 
23) Wilson DO, Rogers RM, Wright EC, et al. Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am Rev Respir 139:1435-1438, 1989
PubMed
24) Ferreira IM, Brooks D, Lacasse Y, et al. Nutritional supplementation for stable chronic obstructive pulmonary disease (Review). Cochrane Database Systematic Review 2005, Issue 2, Art. No. : CD000998
 
25) Sugawara K, Takahashi H, Kasai C, et al. Effects of nutritional supplementation combined with low-intensity exercise in malnourished patients with COPD. Respiratory Medicine : 2010 (in print)
 
26) 渡邊暢 高橋仁美 菅原慶勇ほか. 慢性閉塞性肺疾患患者における呼吸リハビリテーションと栄養療法の併用効果-分岐鎖アミノ酸強化経口栄養剤を用いて-. 総合リハ 38(4):361-367, 2010
 
P.208 掲載の参考文献
1) Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, NHLBI/WHO Workshop Report. Bethesda, National Heart, Lung and Blood Institute. April, 2001 (Update 2006), GOLD wsbsite (www.goldcopd.com), 2006
 
2) Agusti AGN, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 21:347-360, 2003
PubMed
3) 日本呼吸器学会COPDガイドライン第2版作成委員会. COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン第2版, メディカルレビュー社. 東京 : 2004
 
4) Gan WQ, Man SFP, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation : a systemic review and a meta-analysis. Thorax 59:574-580, 2004
 
5) Di Francia M, Barbier D, Mege JL, et al. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 150:1453-1455, 1994
PubMed
6) De Goboy I, Donahoe M, Calhoun WJ, et al. Elevated TNF-α production byperipheral blood monocytes of weight-loosing COPD patients. Am J Respir Crit Care Med 153:633-637, 1996
 
7) Eid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164:1414-1418, 2001
PubMed
8) Creutzberg EC, Schols AM, Weling-Scheepers CA, et al. Characterization of nonresponse to high caloric oral nutritional in depleted patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161:745-752, 2000
PubMed
9) Agusti AGN, Sauleda J, Miralles. C, et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166:485-489, 2002
PubMed
10) van Eeden SF, Tan WC, Suwa T, et al. Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter air pollutants (PM 10). Am J Respir Crit Care Med 164:826-830, 2001
PubMed
11) Vernooy JH, Kucukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease. Soluble tnmor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 166:1218-1224, 2002
 
12) Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of tumor necrosis factor system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161:1179-1184, 2000
 
13) 中里雅光. 肥満・摂食のニューロサイエンス-摂食調節の中枢機構. CLINICAL NEUROSCIENCE 24:873-876, 2006
 
14) Maeda K, Okubo K, Shimomura I, et al. Analysis of an expression profile of genes in the human adipose tissue. Gene 190:227-235, 1997
PubMed
15) 正木孝幸 坂田利家. 食欲調節因子概論-レプチン関連因子を中心に-. 日本臨床 61(増刊号):53-56, 2003
 
16) Takabatake N, Nakamura H, Abe S, et al. Circulating leptin in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 159:1215-1219, 1999
PubMed
17) Schols AMWJ, Creutzberg EC, Buurman WA, et al. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:1220-1226, 1999
 
18) Grunfeld C, Zhao C, Fuller J, et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 97:2152-2157, 1996
PubMed
19) Sarraf P, Frederich RC, Turner EM, et al : Multiple cytokines and acute inflammation raise mouse leptin levels : potential role in inflammatory anorexia. J Exp Med 185:171-175, 1997
PubMed
20) Creutzberg EC, Wouters EFM, Vanderhoven-augustin IML, et al. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 162:1239-1245, 2000
 
21) Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone releasing acylated peptide from stomach. Nature 402:656-660, 1999
PubMed
22) 中里雅光. 新しい消化管ホルモン : グレリン-グレリンの分布と摂食調節作用. BIO Clinica 18:498-503, 2003
 
23) Itoh T, Nagaya N, Yoshikawa M, et al. Elevated plasma ghrelin levels in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170:879-882, 2004
PubMed
24) Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors : a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573-585, 1998
 
25) Matsumura T, Nakayama M, Satoh H, et al. Plasma orexin-A levels and body composition in COPD. Chest 123:1060-1065, 2003
PubMed
26) Debigare R, Marquis K, Cote CH, et al. Catabolic/Anabolic balance and muscle wasting in patients with COPD. Chest 124:83-89, 2003
PubMed
27) Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM 1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 221:286-289, 1996
 
28) Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
PubMed
29) Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules : Adipocyte-derived plasma protein adiponectin. Circulation 100:2473-2476, 1999
PubMed
30) Arita Y, Kihara S, Ouchi N, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105:2893-2898, 2002
PubMed
31) Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24:29-33, 2004
PubMed
32) Young JL, Libby P, Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 88:554-567, 2002
PubMed
33) Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease : meta-analyses of prospective studies. JAMA 279:1477-1482, 1998
PubMed
34) Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 166:333-339, 2002
PubMed
35) Mannino DM, Doherty DE, Buist AS. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality : findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 100:115-122, 2006
 
36) Sin DD, Man SFP. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107:1514-1519, 2003
PubMed
37) Man SFP, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 61:849-853, 2006
PubMed
38) Tomoda K, Yoshikawa M, Itoh T, et al. Elevated circulating plasma adiponectin in underweight patients with chronic obstructive pulmonary disease. Chest (in press)
 
39) Hara T, Fujiwara H, Nakao H, et al. Body composition is related to increase in plasma adiponectin levels rather than training in young obese men. Eur J Appl Physiol 94:520-526, 2005
PubMed
40) Miyamoto K, Aida A, Nishimura M, et al. Gender effect on prognosis of patients receiving long-term home oxygen therapy. Am J Respir Crit Care Med 152:972-976, 1995
PubMed
41) Kitaguchi Y, Fujimoto K, Kubo K, et al. Characteristics of COPD phenotypes classified according to the findings of HRCT. Respir Med 100:1742-1752, 2006
 
42) Matsuyama W, Mitsuyama H, Watanabe M, et al. Effects of omega-3 polyunsaturated fatty acids on inflammatory markers in COPD. Chest 128:3817-3827, 2005
PubMed
43) Broekhuizen R, Wouters EFM, Creutzberg EC, et al. Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease. Thorax 60:376-382, 2005
PubMed
44) Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin adminstration on left ventricular funcion, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110:3674-3679, 2004
 
45) Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest 128:1187-1193, 2005
PubMed

病診連携 ( 在宅療法 )

P.216 掲載の参考文献
1) 日本呼吸管理学会・日本呼吸器学会. 呼吸リハビリテーションに関するステートメント. 日本呼吸管理学会雑誌 11:321-330, 2001
 
2) 日本呼吸器学会COPDガイドライン第2版作成委員会, 編, COPD診断と治療のためのガイドライン 第2版, メディカルレビュー社. 東京 : 2004
 
3) 千住秀明. COPDの治療リハビリテーション. 臨床と研究 86(2):41-45, 2009
 
4) 北川知佳. ADLトレーニング : 塩谷隆信, 編, 包括的呼吸リハビリテーションI基礎編, 新興医学出版社. 東京 : pp256-259, 2007
 
5) 宮川哲夫 高橋仁美. 在宅呼吸リハビリテーション. 理学療法学 32(4):177-182, 2005
Medical*Online
6) Behnke M, Jorres RA, Kirsten D, Magnussen H. Clinical benefits of a combined hospital and home-based exercise programme over 18 months in patients with severe COPD. Monaldi Arch Chest Dis 59(1):44-51, 2003
PubMed
7) Haggerty MC. Stockdale-Woolley R, Nair S. Respi-Care. An innovative home care program for the patient with chronic obstructive pulmonary disease. Chest 100(3):607-612, 1991
PubMed
8) Hernandez MT, Rubio TM, Ruiz FO, Riera HS, Gil RS, Gomez JC. Results of a home-based training program for patients with COPD. Chest 118(1):106-114, 2000
PubMed
9) Wijkstra PJ, TenVergert EM, van der Mark TW, Postma DS, Van Altena R, Kraan J, Koeter GH. Relation of lung function, maximal inspiratory pressure, dyspnoea, and quality of life with exercise capacity in patients with chronic obstructive pulmonary disease, Thorax 49(5):468-472, 1994
PubMed
10) 渡邉暢 高橋仁美ほか. COPD患者における在宅呼吸リハビリテーション継続の有用性. 日本呼吸管理学会雑誌 14:144, 2004
 
11) Brooks D, Krip B, Mangovski-Alzamora S, Goldstein RS. The effect of postrehabilitation programmes among individuals with chronic obstructive pulmonary disease. Eur Respir J 20(1):20-29, 2002
PubMed
12) Ferrari M, Vangelista A, Vedovi E, Falso M, Segattini C, Brotto E, Brigo B, Lo Cascio V. Minimally supervised home rehabilitation improves exercise capacity and health status in patients with COPD. Am J Phys Med Rehabil 83(5):337-343, 2004
PubMed
13) Debigare R, Maltais F, Whittom F, Deslauriers J, LeBlanc P. Feasibility and efficacy of home exercise training before lung volume reduction. J Cardiopulm Rehabil 19(4):235-241, 1999
 
P.221 掲載の参考文献
1) 厚生労働省第14回「医療計画の見直し等に関する検討会」(参考資料)
 
2) Bourbeau J, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease. Arch Intern Med 163:585-591, 2003
PubMed
P.229 掲載の参考文献
1) 日本呼吸器学会COPDガイドライン作成委員会. COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン 第2版, メディカルレビュー社. 東京 : 2004
 
2) 石原英樹. 在宅TIPPVの限界と課題 在宅呼吸管理の新展開. 日本胸部臨床 増刊 : S123-S130, 2005
 
3) 日本呼吸器学会在宅呼吸ケア白書作成委員会. 在宅呼吸ケア白書, 文光堂. 東京 : 2005
 
4) 非侵襲的換気療法研究会. 慢性呼吸不全に対する非侵襲的換気療法ガイドライン. Therapeutic Research 25:5-40, 2004
 
5) 成井浩司. NPPVの導入方法 在宅呼吸管理の新展開. 日本胸部臨床 増刊 : S190-S195, 2005
 
6) 石川悠加. 在宅TIPPVの導入方法と導入後のケア 在宅呼吸管理の新展開. 日本胸部臨床 増刊 : S112-S122, 2005
 
7) 津田徹 吉本美華. これだけは知っておきたい呼吸器薬の使い方 酸素投与の実際. メディチーナ 42(10):1805-1808, 2005
 
8) 津田徹 加賀美由旗 山野七志織 時松初美 末松利加 財津菜穂子 増井太朗 成田直子 中山初美 川俣幹雄 井上博雅 千住秀明 津田稔, 呼吸リハビリテーション主体のデイケアと介護保険. 日本呼吸管理学会誌 12(3):345-350, 2003
 
9) 津田徹 川俣幹雄 尾崎真一 中山初美 山野上志織 時松初美. 医療依存度の高い利用者をケアする上で知っておきたい知識 在宅酸素の患者を受け入れるために. 通所けあ 日総研 : 2003
 
10) 大池貴行 中山初美 津田徹. 入院から在宅に向けた呼吸リハビリテーションプログラム- わたしたちの呼吸ケア向上計画. 呼吸器ケア 4(3) 33-39, 2006
 
11) 末松利加 津田徹 加賀美由旗 中山初美 濱崎喜美代 時松初美 山野上志織 川俣幹雄 津田稔, 慢性呼吸不全患者に対する医療ソーシャルワーカーの取り組みと役割. 日本呼吸管理学会誌 12(3):340-344, 2003
 
12) 山野上志織 川俣幹雄 津田稔 千住秀明 津田徹. デイケアにおける呼吸リハビリテーションの長期継続率. 日本呼吸器学会雑誌 44(1):12-16, 2006
Medical*Online
13) Blanchard AR. Treatment of acute exacerbations of COPD. Clin Cornerstone 5:28-36, 2003
PubMed
14) 津田徹 尾崎真一 町田和彦 川俣幹雄 井上博雅 相澤久道 慢性閉塞性肺疾患COPD肺気腫. 治療 増刊:86, 2004
 
15) Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 152(2):S77-S121, 1995
 
16) Hernandez C. Home hospitalization of exacerbated chronic obstructive pulmonary disease patients. Eur Respir J 21(1):58-67, 2003
PubMed
17) 加賀美由旗 中山初美 鶴田良介 茅原京子 大池貴行 津田稔 津田徹. 在宅呼吸ケア-ケアマネジャーの立場から-. 日本呼吸管理学会誌 15(4):2006
 
18) Donaldson GC. Exacerbations, and time spent outdoors in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 171(5):446-452, 2005
PubMed

書評

最近チェックした商品履歴

Loading...